Braeburn Unveils Innovative Data on Opioid Withdrawal Management at 2026 ASCP Meeting#United_States#Miami#opioid_use_disorder#Buprenorphine#BRIXADI
Braeburn Unveils Innovative Data on Opioid Withdrawal Management at 2026 ASCP Meeting
Braeburn Inc. presented vital findings at the ASCP Annual Meeting, showcasing effective opioid withdrawal management using low-dose buprenorphine injections.
third-news.com
May 28, 2026 at 5:25 PM
Braeburn Unveils Innovative Data on Opioid Withdrawal Management at 2026 ASCP Meeting#United_States#Miami#opioid_use_disorder#Buprenorphine#BRIXADI
Braeburn Showcases Research Insights at CPDD 2026 Annual Meeting on Opioid Use Disorder Treatment#USA#Portland#opioid_use_disorder#Buprenorphine#BRIXADI
Braeburn Showcases Research Insights at CPDD 2026 Annual Meeting on Opioid Use Disorder Treatment
Braeburn highlights new findings on opioid use disorder treatment at CPDD 2026, including data on withdrawal suppression and retention.
third-news.com
June 12, 2026 at 1:04 PM
Braeburn Showcases Research Insights at CPDD 2026 Annual Meeting on Opioid Use Disorder Treatment#USA#Portland#opioid_use_disorder#Buprenorphine#BRIXADI
Exploring cliexa's Clinical AI Innovations: A Case Study with Mayo Clinic#USA#Denver#Mayo_Clinic#opioid_use_disorder#cliexaAI
Exploring cliexa's Clinical AI Innovations: A Case Study with Mayo Clinic
Delve into cliexa's partnership with the Mayo Clinic, showcasing clinical AI solutions and fairness improvements in opioid use disorder detection.
third-news.com
September 15, 2026 at 2:03 PM
Exploring cliexa's Clinical AI Innovations: A Case Study with Mayo Clinic#USA#Denver#Mayo_Clinic#opioid_use_disorder#cliexaAI
Crossroads Treatment Center: Reaching New Heights in Community Care Following Settlement with North Carolina Attorney General#United_States#North_Carolina#Greensboro#opioid_use_disorder#Crossroads_Treatment_Centers
Crossroads Treatment Center: Reaching New Heights in Community Care Following Settlement with North Carolina Attorney General
Crossroads Treatment Center of Greensboro has reached a civil settlement with the North Carolina Attorney General, focusing on past billing practices. The center remains committed to treating those with opioid use disorder in the community.
third-news.com
May 6, 2026 at 6:18 PM
Crossroads Treatment Center: Reaching New Heights in Community Care Following Settlement with North Carolina Attorney General#United_States#North_Carolina#Greensboro#opioid_use_disorder#Crossroads_Treatment_Centers
Significant Increase in Medicaid Patients Receiving Opioid Treatment: New Study Reveals#USA#Research_Triangle_Park#Medicaid#RTI_International#opioid_use_disorder
Significant Increase in Medicaid Patients Receiving Opioid Treatment: New Study Reveals
A new study shows a notable rise in the number of Medicaid beneficiaries receiving medications for opioid use disorder (OUD) in the U.S. This progress varies by state.
third-news.com
April 22, 2026 at 5:26 PM
Significant Increase in Medicaid Patients Receiving Opioid Treatment: New Study Reveals#USA#Research_Triangle_Park#Medicaid#RTI_International#opioid_use_disorder
New Study Published on BRIXADI® for Treating Opioid Dependence in Pregnant Women#United_States#Plymouth_Meeting#Pregnancy#opioid_use_disorder#BRIXADI®
New Study Published on BRIXADI® for Treating Opioid Dependence in Pregnant Women
A groundbreaking clinical trial examines BRIXADI® effectiveness for opioid use disorder in pregnant women, emphasizing safety and abstinence rates.
third-news.com
March 17, 2026 at 2:59 PM
New Study Published on BRIXADI® for Treating Opioid Dependence in Pregnant Women#United_States#Plymouth_Meeting#Pregnancy#opioid_use_disorder#BRIXADI®
Indivior PLC Joins the S&P SmallCap 600 Index: A New Chapter in Healthcare Innovation#USA#Richmond#Indivior#SUBLOCADE#opioid_use_disorder
Indivior PLC Joins the S&P SmallCap 600 Index: A New Chapter in Healthcare Innovation
Indivior PLC's recent inclusion in the S&P SmallCap 600 Index marks a significant milestone for the company in the healthcare sector.
third-news.com
December 22, 2025 at 12:09 PM
Indivior PLC Joins the S&P SmallCap 600 Index: A New Chapter in Healthcare Innovation#USA#Richmond#Indivior#SUBLOCADE#opioid_use_disorder
New Research Unveils Promising Results of Extended-Release Buprenorphine in Fighting Opioid Use Disorder#USA#Richmond#opioid_use_disorder#Buprenorphine#INDV
New Research Unveils Promising Results of Extended-Release Buprenorphine in Fighting Opioid Use Disorder
A recent clinical trial reveals that both doses of extended-release buprenorphine significantly reduce opioid use among high-risk individuals, showcasing the need for innovative treatment strategies.
third-news.com
December 17, 2025 at 4:41 PM
New Research Unveils Promising Results of Extended-Release Buprenorphine in Fighting Opioid Use Disorder#USA#Richmond#opioid_use_disorder#Buprenorphine#INDV
Indivior Unveils New Evidence Supporting Treatment Benefits of Buprenorphine at AMCP Nexus 2025#USA#Richmond#Indivior#opioid_use_disorder#Buprenorphine
Indivior Unveils New Evidence Supporting Treatment Benefits of Buprenorphine at AMCP Nexus 2025
Indivior presented significant findings at AMCP Nexus 2025, highlighting the efficacy and economic advantages of high adherence to monthly injectable buprenorphine in treating opioid use disorder.
third-news.com
November 3, 2025 at 1:26 PM
Indivior Unveils New Evidence Supporting Treatment Benefits of Buprenorphine at AMCP Nexus 2025#USA#Richmond#Indivior#opioid_use_disorder#Buprenorphine
New Clinical Findings Suggest SUBLOCADE® Rapid Induction Boosts Opioid Treatment Retention Rates#United_States#Richmond#SUBLOCADE#opioid_use_disorder#Indivior_PLC
New Clinical Findings Suggest SUBLOCADE® Rapid Induction Boosts Opioid Treatment Retention Rates
Recent clinical trial results highlight the efficacy of rapid SUBLOCADE® induction for improving retention rates in opioid use disorder treatment, particularly for high-risk patients.
third-news.com
October 15, 2025 at 12:38 PM
New Clinical Findings Suggest SUBLOCADE® Rapid Induction Boosts Opioid Treatment Retention Rates#United_States#Richmond#SUBLOCADE#opioid_use_disorder#Indivior_PLC
New Study Highlights Benefits of Extended-Release Buprenorphine for Opioid Use Disorder#United_States#Richmond#Indivior#opioid_use_disorder#Buprenorphine
New Study Highlights Benefits of Extended-Release Buprenorphine for Opioid Use Disorder
Recent findings from Indivior's study reveal that extended-release buprenorphine significantly reduces emergency department visits for opioid use disorder, improving patient outcomes.
third-news.com
July 23, 2025 at 12:14 PM
New Study Highlights Benefits of Extended-Release Buprenorphine for Opioid Use Disorder#United_States#Richmond#Indivior#opioid_use_disorder#Buprenorphine
Indivior Unveils New Insights on Buprenorphine Effectiveness for Opioid Use Disorder at CPDD#United_States#Richmond#Indivior#SUBLOCADE#opioid_use_disorder
Indivior Unveils New Insights on Buprenorphine Effectiveness for Opioid Use Disorder at CPDD
Indivior PLC presents groundbreaking data at CPDD showing that 300 mg of SUBLOCADE may enhance treatment for high fentanyl users suffering from opioid use disorder.
third-news.com
June 19, 2025 at 1:35 PM
Indivior Unveils New Insights on Buprenorphine Effectiveness for Opioid Use Disorder at CPDD#United_States#Richmond#Indivior#SUBLOCADE#opioid_use_disorder
Nest Health Unveils Home-Based Recovery Program for Substance Use Disorders#United_States#New_Orleans#opioid_use_disorder#Nest_Health#home_treatment
Nest Health Unveils Home-Based Recovery Program for Substance Use Disorders
Nest Health's new program offers home-based treatment for opioid use disorders, enhancing support for families facing addiction challenges.
third-news.com
June 3, 2025 at 1:44 PM
Nest Health Unveils Home-Based Recovery Program for Substance Use Disorders#United_States#New_Orleans#opioid_use_disorder#Nest_Health#home_treatment
The Heavy Financial Toll of Opioid Use Disorder in U.S. States#United_States#Washington,_D.C.#Avalere_Health#opioid_use_disorder#Addiction_Costs
The Heavy Financial Toll of Opioid Use Disorder in U.S. States
A recent Avalere Health study finds that opioid use disorder costs U.S. state and local governments $94 billion annually, highlighting the urgent need for effective treatments.
third-news.com
May 20, 2025 at 1:41 PM
The Heavy Financial Toll of Opioid Use Disorder in U.S. States#United_States#Washington,_D.C.#Avalere_Health#opioid_use_disorder#Addiction_Costs
Indivior Reports Strong Q1 2025 Financial Performance and Future Prospects#United_Kingdom#Richmond#financial_results#Indivior#opioid_use_disorder
Indivior Reports Strong Q1 2025 Financial Performance and Future Prospects
Indivior PLC reveals its financial results for Q1 2025, showcasing growth and future prospects in the treatment of opioid use disorder.
third-news.com
April 24, 2025 at 6:10 AM
Indivior Reports Strong Q1 2025 Financial Performance and Future Prospects#United_Kingdom#Richmond#financial_results#Indivior#opioid_use_disorder